MicroPort CardioFlow Medtech Corporation, a medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People's Republic of China and internationally. The company engages in research and development, manufacture, and sale of medical devices in the field of left atrial appendage, and treating valvular heart diseases, as well as properties management. It's product portfolio includes transcatheter aortic valves, left atrial appendage closure, transcatheter mitral valves, transcatheter tricuspid valves, and surgical accessories, as well as procedural accessories; and VitaFlow, VitaFlow Liberty, VitaFlow Liberty Flex, Alwide Plus, AccuSniperTM, AnchorMan LAAC System, AnchorMan LAAA System, and various TAVI, TMV, TTV, and LAA products. In addition, the company provides technical consultation and technical services for medical devices clinical trial. MicroPort CardioFlow Medtech Corporation was founded in 2009 and is headquartered in Shanghai, China.
Часто задаваемые вопросы
В каком секторе работает MicroPort CardioFlow Medtech Corporation (MROPF)?
MicroPort CardioFlow Medtech Corporation относится к сектору Прочее.
Какова текущая цена акций MicroPort CardioFlow Medtech Corporation (MROPF)?
По последним данным, цена акций MicroPort CardioFlow Medtech Corporation составляет 0,65 $, предыдущее закрытие — 0,65 $.
Выплачивает ли MicroPort CardioFlow Medtech Corporation (MROPF) дивиденды?
Нет, MicroPort CardioFlow Medtech Corporation не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у MicroPort CardioFlow Medtech Corporation (MROPF)?
У компании MicroPort CardioFlow Medtech Corporation бета 0.453, что указывает на более низкую волатильность по сравнению с рынком в целом.
